Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Mouse PD-L1 /CD274 /B7-H1 Protein, His tag, 100µg  

Recombinant Mouse PD-L1 /CD274 /B7-H1 Protein, His tag, 100µg

Recombinant Mouse PD-L1 /CD274 /B7-H1 Protein, Phe 19 - Thr 238, produced in human HEK293 cells, His tag

Synonym
recombinant mouse protein PD-L1,CD274,B7-H1,PDCD1L1,PDCD1LG1

More details

PD1-M5220-100

Availability: within 7 days

372,00 €

Background
Programmed cell death 1 ligand 1 (PD-L1) is also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses. B7-H1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. PD-L1 is highly expressed in the heart, skeletal muscle, placenta and lung and weakly expressed in the thymus, spleen, kidney and liver. PD-L1 is expressed on activated T-cells, B-cells, dendritic cells, keratinocytes and monocytes. PD-L1 is up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation and up-regulated in B-cells activated by surface Ig cross-linking. PD-L1 involve in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner.

Source
Recombinant Mouse PD-L1 /CD274 /B7-H1 Protein (Mouse PDL1), His Tag (PD1-M5220) is expressed from human 293 cells (HEK293). It contains AA Phe 19 - Thr 238 (Accession # NP_068693).
Predicted N-terminus: Phe 19

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 26.6 kDa. The protein migrates as 40-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the Mouse PDL1 by the LAL method.

Purity
>95% as determined by SEC-HPLC and SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity"
Joung, Kirchgatterer, Singh et al
Nat Commun (2022) 13 (1), 1606
(2) "DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma"
Starzer, Heller, Tomasich et al
J Immunother Cancer (2022) 10 (3)
(3) "Comparison of the immune activation capacities of fucoidan and laminarin extracted from Laminaria japonica"
An, Hwang, Kim et al
Int J Biol Macromol (2022)
Showing 1-3 of 19373 papers.

Citations

(1) "Novel anti-PD-1 antibodies"
Authors: X Qian, et al
Journal: US20190330348A1 2019
Application: ELISA
(2) "PD-L1-based cancer vaccine elicits antitumor immunity in a mouse melanoma model"
Authors: Z Lin, et al
Journal: Molecular Therapy: Oncolytics 2019
Application: PD-L1 PD-1 Blockade assay (ELISA)
(3) "PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis"
Authors: Wang Aijun, et al.
Journal: US20170355770A1 2017
Application: Immunization